This K12 Competitive Renewal Application describes our Program at the University of Pennsylvania (PENN) and the Children's Hospital of Philadelphia (CHOP) for training the next generation of outstanding clinical and translational non-malignant (""""""""classic"""""""") hematology investigators, including adult and pediatric transfusion investigators. During the first iteration of this K12, our Program was very successful with all fiv of our K12 scholars rising to become Assistant Professors in Hematology Divisions at academic medical centers around the county. The academic environment and resources at PENN and CHOP provide a fertile training ground, and our Institution is committed to continue to contribute both materially and intellectually to the success of this Training Program. We also recently opened the Institute for Translational Medicine and Therapeutics (ITMAT), and the Blood Center at PENN &CHOP. These new entities expand the already rich environment for training our scholars, and provide an ideal setting for this Career Development Program, which will be structured to cover: Hemostasis, Red Cell Disorders, Immune Hematology and Transfusion Medicine, Stem Cells, Bone Marrow Failure and Myeloproliferative Disorders to meet the intent of this K12 Competitive.

Public Health Relevance

There is currently a national shortage of physicians who are skilled at investigating non- malignant blood diseases. This is an application to continue a training program that will guide scholars as they acquire the necessary skills to design and execute clinical trials aimed at improving the care of patients with these blood disorders. This training program involves rigorous classroom work, intensive mentoring, and hands-on experience.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Mondoro, Traci
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Babushok, Daria V; Stanley, Natasha; Xie, Hongbo M et al. (2017) Clonal Replacement Underlies Spontaneous Remission in Paroxysmal Nocturnal Haemoglobinuria. Br J Haematol 176:487-490
Betensky, Marisol; Babushok, Daria; Roth, Jacquelyn J et al. (2016) Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia. Cancer Genet 209:1-10
Bhoj, Vijay G; Arhontoulis, Dimitrios; Wertheim, Gerald et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128:360-70
Ellebrecht, Christoph T; Bhoj, Vijay G; Nace, Arben et al. (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179-84
Babushok, Daria V; Grignon, Anne-Laure; Li, Yimei et al. (2016) Disrupted lymphocyte homeostasis in hepatitis-associated acquired aplastic anemia is associated with short telomeres. Am J Hematol 91:243-7
Babushok, Daria V; Bessler, Monica; Olson, Timothy S (2016) Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma 57:520-36
Babushok, Daria V; Olson, Timothy S; Bessler, Monica (2015) Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med 373:1673
Wong, Trisha E; Delaney, Meghan; Gernsheimer, Terry et al. (2015) Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study. Pediatr Crit Care Med 16:264-9
Babushok, Daria V; Perdigones, Nieves; Perin, Juan C et al. (2015) Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet 208:115-28
Oshrine, Benjamin R; Olson, Timothy S; Bunin, Nancy (2014) Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease. Pediatr Blood Cancer 61:1852-9

Showing the most recent 10 out of 35 publications